AstraZeneca

AZN · NYSE · USD

$156.90−0.51%−$0.80

Close · October 2, 2026

At a glance

Revenue growth
+8.63%
2025 vs 2024
Net income growth
+45.34%
2025 vs 2024
Net margin
17.4%
2024: 13.0%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue15,38415,28815,50315,19114,45713,58814,89113,56512,93812,67912,02411,492
Cost of revenue2,5312,6733,1702,7922,4732,2412,1563,0812,1832,2182,0802,095
Gross profit12,85312,61512,33312,39911,98411,34712,73510,48410,75510,4619,9449,397
Selling, general and administrative5,7245,0275,3185,1965,0074,6274,4745,2885,0614,6303,7864,929
Research and development3,6723,4713,6153,6303,5483,1593,3373,1153,0082,7832,8872,584
Operating income3,6094,2723,3473,6623,5083,6084,9622,1062,7463,1153,3411,954
EBIT3,6094,2723,3473,6623,5083,6084,9622,1062,7463,1153,3411,954
EBITDA5,1935,6384,1135,2114,8974,8925,2493,9234,0254,3704,2333,180
Interest expense43539315543443934913945744341338.0392
Pre-tax income2,7993,9142,6293,2443,1273,4021,6661,8282,3972,8008971,652
Income tax291833300709679481166395469620-62.0274
Net income2,5073,0802,3262,5332,4502,9161,5001,4291,9272,1799601,374
Net income to common shareholders2,5073,0802,3262,5332,4502,9161,5001,4291,9272,1799601,374
Basic EPS1.621.991.501.631.581.880.970.921.241.410.620.89
Diluted EPS1.611.971.481.621.571.870.960.911.231.400.610.88
Average shares (basic)1,5511,5491,5511,5511,5501,5501,5501,5501,5491,5491,5491,549
Average shares (diluted)1,5601,5611,5631,5611,5591,5611,5621,5621,5601,5601,5611,560
Dividend per share1.06—2.170.001.03—2.100.001.00—1.97—